Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation

Journal article

Peer reviewed

Yue Pan, Yue Zeng, Yurong Peng, Xiaohan Liu, Yizheng Li and Fang Wu

European journal of cancer (1990), Vol.165, pp.154-156

2022-04

PMID: 35235872

Abstract

Adenocarcinoma of Lung - drug therapy

Adenocarcinoma of Lung - genetics

Humans

Lung Neoplasms - drug therapy

Lung Neoplasms - genetics

Lung Neoplasms - pathology

Mutation

Oncogene Proteins, Fusion - genetics

Organophosphorus Compounds

Pyrimidines

Receptor Protein-Tyrosine Kinases - genetics

1 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.199 Lung Cancer; 1.199.581 NSCLC
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation
Creators: Yue Pan - Second Xiangya Hospital of Central South University
Yue Zeng - Second Xiangya Hospital of Central South University
Yurong Peng - Second Xiangya Hospital of Central South University
Xiaohan Liu - Second Xiangya Hospital of Central South University
Yizheng Li - Second Xiangya Hospital of Central South University
Fang Wu - Second Xiangya Hospital of Central South University
Publication Details: European journal of cancer (1990), Vol.165, pp.154-156
Academic Unit: Miller School of Medicine; UMMG Department of Public Health Sciences Research
Language: English
Resource Type: Journal article
PMID: 35235872
Record Identifier: 991031786589602976